These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 19845417)

  • 21. Is visual field constriction in epilepsy patients treated with vigabatrin reversible?
    Schmidt T; Rüther K; Jokiel B; Pfeiffer S; Tiel-Wilck K; Schmitz B
    J Neurol; 2002 Aug; 249(8):1066-71. PubMed ID: 12195456
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vigabatrin-associated visual field constriction in a longitudinal series. Reversibility suggested after drug withdrawal.
    Fledelius HC
    Acta Ophthalmol Scand; 2003 Feb; 81(1):41-6. PubMed ID: 12631018
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Retinal nerve fiber layer thickness in vigabatrin-exposed patients.
    Clayton LM; Dévilé M; Punte T; Kallis C; de Haan GJ; Sander JW; Acheson J; Sisodiya SM
    Ann Neurol; 2011 May; 69(5):845-54. PubMed ID: 21246602
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Visual field defects in patients taking vigabatrin.
    Midelfart A; Midelfart E; Brodtkorb E
    Acta Ophthalmol Scand; 2000 Oct; 78(5):580-4. PubMed ID: 11037919
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characteristics of a unique visual field defect attributed to vigabatrin.
    Wild JM; Martinez C; Reinshagen G; Harding GF
    Epilepsia; 1999 Dec; 40(12):1784-94. PubMed ID: 10612345
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of vigabatrin in childhood seizure disorders: results from a clinical audit.
    Prasad AN; Penney S; Buckley DJ
    Epilepsia; 2001 Jan; 42(1):54-61. PubMed ID: 11207785
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The function of eye and vision system in children and youth treated with vigabatrin--our own experiences].
    Pojda-Wilczek D; Emich-Widera E; Herba E; Pojda SM; Marszał E
    Klin Oczna; 2005; 107(10-12):654-7. PubMed ID: 16619812
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Binasal visual field defects are not specific to vigabatrin.
    Gonzalez P; Sills GJ; Parks S; Kelly K; Stephen LJ; Keating D; Dutton GN; Brodie MJ
    Epilepsy Behav; 2009 Nov; 16(3):521-6. PubMed ID: 19815465
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In utero exposure to vigabatrin: no indication of visual field loss.
    Lawthom C; Smith PE; Wild JM
    Epilepsia; 2009 Feb; 50(2):318-21. PubMed ID: 18616557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does the Swedish Interactive Threshold Algorithm (SITA) accurately map visual field loss attributed to vigabatrin?
    Conway ML; Hosking SL; Zhu H; Cubbidge RP
    BMC Ophthalmol; 2014 Dec; 14():166. PubMed ID: 25539569
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Visual field severity indices demonstrate dose-dependent visual loss from vigabatrin therapy.
    Conway M; Cubbidge RP; Hosking SL
    Epilepsia; 2008 Jan; 49(1):108-16. PubMed ID: 18184224
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Visual function is stable in patients who continue long-term vigabatrin therapy: implications for clinical decision making.
    Paul SR; Krauss GL; Miller NR; Medura MT; Miller TA; Johnson MA
    Epilepsia; 2001 Apr; 42(4):525-30. PubMed ID: 11440348
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Visual field constriction in 91 Finnish children treated with vigabatrin.
    Vanhatalo S; Nousiainen I; Eriksson K; Rantala H; Vainionpää L; Mustonen K; Aärimaa T; Alen R; Aine MR; Byring R; Hirvasniemi A; Nuutila A; Walden T; Ritanen-Mohammed UM; Karttunen-Lewandowski P; Pohjola LM; Kaksonen S; Jurvelin P; Granström ML
    Epilepsia; 2002 Jul; 43(7):748-56. PubMed ID: 12102679
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Does vigabatrin treatment for infantile spasms cause visual field defects? An international multicentre study.
    Riikonen R; Rener-Primec Z; Carmant L; Dorofeeva M; Hollody K; Szabo I; Krajnc BS; Wohlrab G; Sorri I
    Dev Med Child Neurol; 2015 Jan; 57(1):60-7. PubMed ID: 25145415
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Balancing clinical benefits of vigabatrin with its associated risk of vision loss.
    Pellock JM
    Acta Neurol Scand Suppl; 2011; (192):83-91. PubMed ID: 22061183
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Visual field defects in pediatric patients on vigabatrin monotherapy.
    Ascaso FJ; Lopez MJ; Mauri JA; Cristobal JA
    Doc Ophthalmol; 2003 Sep; 107(2):127-30. PubMed ID: 14661902
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Full-field ERG and visual fields in patients 5 years after discontinuing vigabatrin therapy.
    Kjellström U; Lövestam-Adrian M; Andréasson S; Ponjavic V
    Doc Ophthalmol; 2008 Sep; 117(2):93-101. PubMed ID: 18188629
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Visual field disturbances in epileptic patients treated with vigabatrin (sevril)].
    Gross-Tsur V; Lahat E; Banin E; Shahar E; Shalev R
    Harefuah; 2002 Mar; 141(3):247-9, 315. PubMed ID: 11944216
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Retinal function abnormalities in patients treated with vigabatrin.
    Banin E; Shalev RS; Obolensky A; Neis R; Chowers I; Gross-Tsur V
    Arch Ophthalmol; 2003 Jun; 121(6):811-6. PubMed ID: 12796251
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects.
    Kälviäinen R; Nousiainen I; Mäntyjärvi M; Nikoskelainen E; Partanen J; Partanen K; Riekkinen P
    Neurology; 1999 Sep; 53(5):922-6. PubMed ID: 10496247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.